Novavax (Nasdaq:NVAX) today provided a corporate update and announced its financial results for the fourth quarter and twelve months ended December 31, 2017. As quoted in the press release: “This influenza season in the Northern Hemisphere has resulted in a serious public health epidemic, largely because of the H3N2 flu strain and the inability of …

Novavax (Nasdaq:NVAX) today provided a corporate update and announced its financial results for the fourth quarter and twelve months ended December 31, 2017.

As quoted in the press release:

“This influenza season in the Northern Hemisphere has resulted in a serious public health epidemic, largely because of the H3N2 flu strain and the inability of current vaccines to provide adequate protection, particularly to older adults and other vulnerable populations,” said Gregory M. Glenn, M.D., President of Research and Development. “Our NanoFlu vaccine’s head-to-head performance against IIV3-HD demonstrated that it has the potential to address two primary confounding factors related to poor vaccine efficacy: virus drift and vaccine mutation resulting from egg-based manufacturing. With these findings, we are able to initiate manufacturing and clinical operations activities to support our next step, a Phase 2 trial of a quadrivalent formulation of our NanoFlu vaccine, scheduled to begin in the third quarter of this year.”

Click here to read the full press release.